3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Curanex Pharmaceuticals disclosed two putative securities class actions in New York state court tied to its August 2025 initial public offering. The suits allege material misstatements and omissions in the IPO registration statement and prospectuses, including risks of stock-price manipulation and underwriter due diligence failures; the Company says it intends to defend them vigorously. The cases are at a preliminary stage and seek unspecified damages, so shareholders cannot yet assess the potential financial effect.
Morales action filed July 23, 2026 (Index No. 159271/2026), naming the Company and its underwriters among more than 20 other defendants
Lovett action filed September 14, 2026 (Index No. 655238/2026), also naming the Company's former CFO, directors and independent auditor
Both complaints seek unspecified compensatory damages and rescission or rescissory damages; neither asserts a fraud claim against the Company
Response deadlines: November 15, 2026 for Morales and December 11, 2026 for Lovett
Medalist Diversified filed a Certificate of Correction with Maryland on October 19, 2026, stating that a charter amendment approved at its June 16, 2026 annual meeting is of no force or effect. The company said the amendment, which restricted certain stock transfers to protect net operating loss and net capital loss tax benefits, did not receive the required stockholder vote. The board says it intends to seek stockholder approval again at a special meeting.
Certificate of Correction filed with Maryland SDAT on October 19, 2026
Charter Amendment originally filed with SDAT on June 17, 2026, after June 16, 2026 annual meeting
Amendment would have limited transfers that raise a holder's stake from under 4.9% to 4.9% or more
Over 95% of votes cast supported the proposal, but the required vote was not met
Collegium Pharmaceutical agreed on October 15, 2026 to settle all disputes with Grünenthal GmbH, including a patent infringement lawsuit over the Nucynta ER authorized generic. As part of the settlement, the company's license agreement with Grünenthal was terminated in its entirety, and the company made a $17 million payment, after which no further royalties are due under that license.
Settlement agreement dated October 15, 2026 resolves all disputes, including the Nucynta Litigation filed in February 2026 in the District of New Jersey
Collegium paid Grünenthal $17 million; the Grünenthal License terminated effective October 15, 2026
No further royalties will be due under the Grünenthal License; Grünenthal assigned certain Nucynta-related patents to Collegium and moved to dismiss the lawsuit
ZoomInfo signed a memorandum of understanding on October 16, 2026, setting terms for a proposed settlement of a securities class action filed on September 4, 2024. The settlement provides for a $44 million payment to the class, a portion of which is expected to be covered by remaining insurance funds, and requires approval by the Washington District Court. The settlement would not resolve related shareholder derivative lawsuits, a related opt-out action, or a separate class action filed on June 25, 2026.
$44 million payment to the putative class, with a portion expected to be covered by remaining insurance funds
Memorandum of understanding executed October 16, 2026; subject to preliminary and final approval by the Washington District Court
Settlement would not resolve shareholder derivative suits, an opt-out direct action, or the class action filed June 25, 2026
PLAYSTUDIOS received written notice from Nasdaq on October 15, 2026 that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market, and the matter is now closed. The company had received a non-compliance notice on November 5, 2025, and addressed it through a 1-for-10 reverse stock split effective September 30, 2026.
Nasdaq notice dated October 15, 2026 confirms compliance with the $1.00 minimum bid price rule (Listing Rule 5550(a)(2))
Class A common stock closed at or above $1.00 for ten consecutive business days, October 1 through October 14, 2026
Reverse stock split of 1-for-10 for Class A and Class B common stock; Class A began trading split-adjusted on October 1, 2026
BioCardia said the FDA has accepted its revised De Novo pre-submission package for marketing clearance of its Helix catheter, and it expects FDA substantive review and a meeting this quarter. The filing does not report any financial results, and clearance is not yet granted, so the update is a regulatory milestone rather than a change in reported financial performance.
FDA accepted the revised De Novo pre-submission package, announced October 19, 2026
Company met with FDA in May 2026 and FDA confirmed and accepted the meeting minutes in August 2026
Revised package was re-submitted in September 2026 and BioCardia expects FDA substantive review and a meeting this quarter
Company cites clinical data from fifteen clinical trials including nearly five hundred patients
Ultragenyx and Baylor Research Institute settled patent litigation with Navinta LLC over patents covering DOJOLVI oral liquid. Navinta will receive a non-exclusive, royalty-free license to market a generic version starting January 1, 2033, which would extend to July 1, 2033 if pediatric exclusivity is granted. The filing does not give a financial impact, and other ANDA patent litigation on DOJOLVI remains pending.
Settlement with Navinta LLC resolves patent litigation filed in the U.S. District Court for the District of New Jersey
Navinta's generic DOJOLVI license begins January 1, 2033, or July 1, 2033 if pediatric exclusivity is granted
Similar patent litigation against other ANDA filers remains pending in the same court
Settlement agreement will be submitted to the FTC and the U.S. Department of Justice
Clene Inc. announced that it submitted a New Drug Application to the FDA earlier in October 2026 seeking accelerated approval of CNM-Au8 for amyotrophic lateral sclerosis (ALS). The filing contains no financial figures and does not state a review timeline. For shareholders, the submission advances the company's lead program toward a possible FDA decision, but approval is not assured.
NDA submitted earlier in October 2026 seeking accelerated approval of CNM-Au8 for ALS
Application is based on neurofilament light chain biomarker data and clinical outcomes
Company says it continues preparing for the confirmatory Phase 3 RESTORE-ALS study
Press release dated October 19, 2026, furnished as Exhibit 99.1
The FDA accepted for filing a supplemental New Drug Application for REZZAYO (rezafungin) for the prophylaxis of invasive fungal disease and granted Priority Review, with a PDUFA target action date in Q1 2027. The application was submitted by partner Mundipharma and is supported by the Phase III ReSPECT study. Acceptance does not assure approval, and CorMedix is targeting promotional efforts beginning in H2 2027 if the indication is approved.
FDA accepted the sNDA for filing and granted Priority Review
PDUFA target action date is in Q1 2027
Application was submitted by Mundipharma, CorMedix's global development partner
If approved, CorMedix is targeting promotional efforts beginning in H2 2027
Rekor Systems filed a complaint on October 16, 2026, in the Delaware Court of Chancery against former director Viraj Mehta, alleging breach of his fiduciary duty of loyalty in connection with the company's December 2025 financing. The company seeks damages, disgorgement and restitution of director compensation, but the allegations have not been adjudicated and the company cannot predict the outcome.
Complaint filed October 16, 2026; the Board authorized the action and the company announced it on October 19, 2026.
Complaint alleges Mehta failed to disclose material facts and misrepresented his familiarity with the buyer in the December 2025 financing, which included 8,571,428 seven-year warrants.
Relief sought includes compensatory damages, disgorgement, restitution of director compensation and other relief.
The filing states Rekor faces a $15 million Revenue Notes maturity on December 15, 2026, which it cannot meet without refinancing, restructuring or new capital.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.